Pamela S. Douglas, MD; Michael G. Nanna, MD, MHS; Michelle D. Kelsey, MD; et al.
open access
JAMA Cardiol. 2023;8(10):904-914. doi:10.1001/jamacardio.2023.2595
This randomized clinical trial investigates the optimal initial evaluation pathway to reduce unnecessary testing referral for patients with suspected coronary artery disease who are symptomatic but in stable condition.
James E. Udelson, MD; Michelle D. Kelsey, MD; Michael G. Nanna, MD, MHS; et al.
free access
JAMA Cardiol. 2023;8(10):915-924. doi:10.1001/jamacardio.2023.2614
This study assesses process of care and health outcomes in people identified as minimal risk for coronary artery disease when testing is deferred.
Elizabeth L. Tung, MD, MS; Kristen E. Wroblewski, MS; Jennifer A. Makelarski, PhD, MPH; et al.
free access
JAMA Cardiol. 2023;8(10):927-935. doi:10.1001/jamacardio.2023.2672
This cohort study examines the association of childhood exposure to parental incarceration with cardiovascular risk among a nationally representative sample of US adults.
-
Editor's Note
Adverse Childhood Experiences as Social Determinants of Cardiovascular Health
Ann Marie Navar, MD, PhD; Sadiya S. Khan, MD, MSc; Clyde W. Yancy, MD, MSc
JAMA Cardiol
Iulia Iatan, MD, PhD; Meijiao Guan, PhD; Karin H. Humphries, DSc; et al.
free access
JAMA Cardiol. 2023;8(10):937-945. doi:10.1001/jamacardio.2023.2731
This systematic review and meta-regression evaluates the association between coronary plaque regression induced by lipid-lowering therapies and major adverse cardiovascular events.
Georgios Georgiopoulos, MD; Simon Kraler, MD; Matthias Mueller-Hennessen, MD; et al.
open access
JAMA Cardiol. 2023;8(10):946-956. doi:10.1001/jamacardio.2023.2741
This cohort study assesses the incremental predictive value of a modified Global Registry of Acute Coronary Events score incorporating high-sensitivity cardiac troponin T at presentation, a surrogate of the extent of myocardial injury.
Zhuang Tian, MD; Liwen Li, MD; Xiaoyan Li, MD; et al.
open access
JAMA Cardiol. 2023;8(10):957-965. doi:10.1001/jamacardio.2023.3030
This randomized clinical trial evaluates the safety and efficacy of mavacamten compared with placebo for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy.
Milind Y. Desai, MD, MBA; Anjali Owens, MD; Kathy Wolski, MPH; et al.
free access
JAMA Cardiol. 2023;8(10):968-977. doi:10.1001/jamacardio.2023.3342
This randomized clinical trial investigates the long-term efficacy of mavacamten in reducing the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy.